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Background: Shedding of nanoparticles from the cell membrane is a common process in all 
cells. These nanoparticles are present in body fluids and can be harvested by isolation. To collect 
circulating nanoparticles from blood, a standard procedure consisting of repeated centrifuga-
tion and washing is applied to the blood samples. Nanoparticles can also be shed from blood 
cells during the isolation process, so it is unclear whether nanoparticles found in the isolated 
material are present in blood at sampling or if are they created from the blood cells during the 
isolation process. We addressed this question by determination of the morphology and identity 
of nanoparticles harvested from blood.
Methods: The isolates were visualized by scanning electron microscopy, analyzed by flow 
cytometry, and nanoparticle shapes were determined theoretically.
Results: The average size of nanoparticles was about 300 nm, and numerous residual blood 
cells were found in the isolates. The shapes of nanoparticles corresponded to the theoretical 
shapes obtained by minimization of the membrane free energy, indicating that these nanoparticles 
can be identified as vesicles. The concentration and size of nanoparticles in blood isolates was 
sensitive to the temperature during isolation. We demonstrated that at lower temperatures, the 
nanoparticle concentration was higher, while the nanoparticles were on average smaller.
Conclusion: These results indicate that a large pool of nanoparticles is produced after blood 
sampling. The shapes of deformed blood cells found in the isolates indicate how fragmentation 
of blood cells may take place. The results show that the contents of isolates reflect the properties 
of blood cells and their interaction with the surrounding solution (rather than representing only 
nanoparticles present in blood at sampling) which differ in different diseases and may therefore 
present a relevant clinical parameter.
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Introduction
Early studies reported that “platelet dust” contributing to the coagulation process exists 
in blood plasma.1 It was shown subsequently that nanoparticles are shed from membranes 
of erythrocytes during storage2–4 or in vitro in suspensions of cells after the addition of 
different stimuli.5–7 Stimulation of platelets by externally added substances also induces 
budding and shedding of nanoparticles.8 In the literature, nanoparticles created through 
membrane budding are also called microvesicles, the corresponding process of their 
formation is called microvesiculation, while platelet-derived nanoparticles are called 
microparticles. Vesiculation was studied in cancer cells9–13 and was shown in vivo to 
be connected to the impact of cancer-associated coagulopathies.14–17 Furthermore, 
nanoparticles have also been found in isolates from other body fluids, such as synovial 
fluid of inflamed joints,18 pleural fluid,19 ascites,19 saliva,20,21 and urine.22
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Based on accumulated experimental evidence, nanopar-
ticles are now considered membrane-enclosed compartments 
of the cell interior that are released into the surrounding 
solution during the final stage of the budding process. They 
are involved in cell–cell communication23–28 and may play 
a role in the coagulation process inside blood vessels.29 
  Cell-derived nanoparticles should therefore be considered 
when studying relevant physiological and pathophysiologi-
cal processes. It has been suggested that determining the 
concentration and content of nanoparticles in blood may help 
in the early and low-invasive diagnosis of various common 
diseases that have extensive medical, ethical, and economic 
consequences.30–32
It would be beneficial to perform diagnosis on samples of 
peripheral blood instead of on samples obtained by biopsy. It 
is believed that blood contains circulating nanoparticles33–36 
carrying information on clinical status and that these nanopar-
ticles can be harvested by isolation. Methods of isolation have 
been developed consisting mainly of repetitive centrifugation 
and washing of samples and then assessing the nanoparticles 
by flow cytometry.35–39 The results of numerous clinical 
studies showed that the concentration of nanoparticles in 
isolates is increased in patients with a variety of diseases 
compared with healthy controls.30,40,41 However, a method 
based on the isolation and assessment of nanoparticles from 
blood that would be of satisfactory repeatability and accuracy 
and therefore suitable for diagnosis and treatment in clinical 
practice has not yet been established. Also the mechanisms 
responsible for budding and vesiculation, including the pro-
cesses that occur during the isolation procedure, are poorly 
understood.
Recently, attention has been devoted to the different 
effects of an isolation procedure on the contents of the isolate 
(reviewed by Yuana et al42). To solve problems arising from 
preanalytical and analytical issues in the analysis of blood 
nanoparticles, it is necessary to standardize the isolation 
protocol. However, we believe that in order to establish 
assessment of nanoparticles as a clinically relevant method, 
standardization alone is insufficient, as without an under-
standing of the underlying mechanisms, parameters that have 
important effects on the result may be overlooked.
The aim of this study was thus to improve knowledge 
of the mechanisms and processes taking place during the 
isolation of nanoparticles and to reveal the morphology and 
identity of particles in the isolated material. In particular, we 
tried to answer the question whether nanoparticles found in 
the isolate are present in blood at sampling or are they created 
from blood cells during the isolation process. In the latter 
case, clinical results importantly reflect the vesiculability of 
cells, mostly platelets. For example, due to interaction of 
native nanoparticles with platelets, platelets are a potential 
pool of tumor material and also a source of tumor seeding 
following removal of a tumor from the body. To diminish 
the probability of metastases spreading, possible simple 
therapeutic procedures could be suggested based on the 
removal of a portion of the platelets after tumor resection 
and their replacement with platelets from a healthy donor. 
Further, subsequent attempts to optimize platelet number 
could complement other therapeutic procedures by slowing 
down or even stopping tumor progression.
It is therefore likely that information on the source and 
identity of nanoparticles could shed light on the interpreta-
tion of clinical studies involving determination of nanopar-
ticles in blood. Pursuing a study on the origin and identity 
of nanoparticles in vivo, examining the effects of blood cell 
fragmentation during isolation should also improve under-
standing of the basic mechanisms of cell–cell communication 
and tumor progression.
Materials and methods
Subjects
For the series of experiments on the effect of temperature, 
blood samples were collected from 56 subjects (students and 
staff) with no record of disease, after a 12-hour overnight 
fast. Up to eight samples were processed within a single 
  experiment. The chosen temperature was kept constant dur-
ing the isolation procedure. The nanoparticles in fresh isolates 
were counted by flow cytometry immediately after isolation. 
We discarded 14 samples because the buffer used for washing 
was found to be contaminated by bacteria. For final analysis 
we included samples obtained from 42 subjects with no 
record of disease (29 females and 13 males). In a second set 
of experiments, blood was collected from seven subjects with 
no record of disease (four females and three males) after a 
12-hour fast. Isolation was first performed at 37°C and then 
a second blood sample was collected from the same subjects 
in the same consecutive order and the isolation performed 
at 20°C. The procedure was then again repeated at 4°C. The 
volunteers, consisting of staff and the authors, did not eat or 
drink over the period of blood sampling and were requested 
to refrain from physical activity. The isolation procedures 
were performed at the three different temperatures in a single 
day so that fresh isolates could be assessed using the same 
setting of the flow cytometer. Blood sampling was performed 
by the same nurse in all the experiments that examined the 
effect of temperature on isolation of nanoparticles.
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Six experiments were performed between 2007 and 
2010 to study the correlation between the concentrations of 
nanoparticles in the isolates and platelets in the blood. A total 
of 193 subjects with no record of disease were included in 
these experiments. The volunteers consisted of students of 
the Faculty of Medicine and Faculty of Veterinary Medicine, 
University of Ljubljana, staff of collaborating institutions and 
authors, and 101 participants in the 16th European Veterans 
Athletic Championships, held in Stadia, Ljubljana, from 
July 23 to August 3, 2008.
Blood samples for scanning electron microscope imaging 
of nanoparticles were donated by a patient (female, 60 years) 
with locally advanced pancreatic cancer, two of the authors 
with no record of disease (male, 29 years, female, 28 years), 
and a healthy mare (5 years, 500 kg). Mare’s blood was 
used because the large size of the animal allowed collection 
of a larger volume of blood with minimal discomfort to the 
animal.
Ethical issues
All body fluids were acquired with the written consent of the 
volunteers, patients, and the owner of the mare. The study 
was approved by the National Ethics Committee. In patients, 
blood samples for experiments were taken only when blood 
was needed to be collected for therapeutic reasons, within the 
same phlebotomy. Likewise, in students, blood samples for 
experiments were taken when the blood was being collected 
for obligatory checkups, within the same phlebotomy. For the 
experiments only, blood was taken from authors, staff, and 
athlete veterans. For the study of the effect of temperature 
on the concentration and the size of nanoparticles in isolates, 
50 mL samples of blood were taken from two of the authors 
and the mare.
Blood sampling
Blood was collected in 2.7 mL tubes containing 270 µL 
trisodium citrate at a concentration of 0.109 mol/L. Evacuated 
tubes (BD Vacutainers, Becton Dickinson, CA) were used in 
all the experiments. A 21-gauge needle (length 70 mm, inner 
radius 0.4 mm, Microlance, Becton Dickinson, NJ) was used 
for blood sampling in all the experiments, with the exception 
of the experiment in which isolation was performed at three 
different temperatures in a single day. In that experiment, a 
21 gauge needle (Tik d.o.o., Kobarid, Slovenia) was used. 
During this experiment, the covers of the vacutubes were 
removed prior to sampling and the blood was allowed to drop 
freely into the tube. Variation in the acquired volumes did 
not exceed 15%. In these studies, the tubes were incubated 
in a rotating centrifuge at the desired temperature and kept 
in a water bath during handling of the samples. The samples 
were left in the water bath for several minutes to attain the 
desired temperature before centrifugation.
Isolation of nanoparticles
Centrifugation of the samples started within 20 minutes 
after acquisition of the first sample. In order to separate the 
cells from plasma, the samples were centrifuged at 1550 × g 
for 20 minutes in a Centric 400/R centrifuge (Tehtnica 
Železniki, Železniki, Slovenia). The upper 250 µL of plasma 
was removed slowly using a tip with a wide opening and 
placed in a 1.5 mL Eppendorf tube. The samples were then 
centrifuged at 17570 × g for 30 minutes in a Centric 200/R 
centrifuge (Tehtnica Železniki). The supernatant (225 µL) 
was discarded and the pellet (25 µL) resuspended in 225 µL 
citrated phosphate-buffered saline. The samples were cen-
trifuged again at 17570× g for 30 minutes, the supernatant 
(225 µL) discarded and the pellet (25 µL) resuspended in 
75 µL of citrated phosphate-buffered saline.
Flow cytometric analysis
Flow cytometric analysis was performed using an Altra Flow 
Cytometer (Beckman Coulter Inc, Fullerton, CA) with a 
488 nm water-cooled laser. The Coulter EXPO32 software 
was used for data acquisition and analysis of the results. 
The presence of particles (residual cells and nanoparticles) 
was determined by forward and side scatter parameters. The 
flow count of fluorospheres (10 µm, Beckmann Coulter) at a 
known concentration (1 × 106/mL) was used to determine the 
concentration of nanoparticles. At least 10,000 events were 
recorded in each sample analysis. The size of the particles 
in the sample was estimated by the mean intensity of the 
forward scattered light.
Scanning electron microscopy
The nanoparticles were suspension-fixed in 1% glutaralde-
hyde dissolved in phosphate-buffered saline/citrate buffer for 
60 minutes at 22°C, post-fixed for 60 minutes at 22°C in 1% 
OsO4 dissolved in 0.9% NaCl, dehydrated in a graded series of 
acetone/water (50%–100%, v/v) and critical point dried. At the 
Åbo Akademi University, the samples were gold-sputtered, 
and examined using a LEO Gemini 1530 (LEO, Oberkochen, 
Germany) scanning electron microscope, while at FEI Quanta, 
the samples were iridium-coated, and examined using a Quanta 
TM 250 FEG (FEI, Hillsboro, OR) scanning electron micro-
scope. Drying may have caused shrinking of objects up to 20%, 
the effect being more pronounced for larger objects (cells).
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Determination of theoretical shapes
The shapes of the nanoparticles at equilibrium were calcu-
lated by minimization of the membrane free energy,43 taking 
into account possible orientational ordering of membrane 
constituents in highly anisotropically curved regions, and 
also assuming rotational symmetry of nanoparticles with 
respect to the symmetry axis.44,45 Membrane area, enclosed 
volume, and average mean curvature were kept constant dur-
ing minimization. The system of differential equations was 
solved numerically, as described by Iglič et al.45
Determination of average size  
of nanoparticles
The size of the nanoparticles was estimated from micro-
graphs by measuring the linear dimension of the nanoparticle 
cross-sections, inclined at an angle of 45° with respect to 
the coordinate system determined by the principal axes. All 
clearly visible shapes within a frame were considered. The 
measurements were carried out using Corel Draw software 
(Corel Corporation, Ottawa, Canada).
Results
Figure 1 shows a typical scanning electron micrograph of an 
isolate from the blood of a healthy human donor, exhibiting 
a mass of nanoparticles and many residual erythrocytes. 
Figure 2 shows scanning electron micrographs of chosen 
regions of an isolate from the blood of a healthy human 
donor. Heparin (A–D) and trisodium citrate (E, F) were used 
as the anticoagulants. Numerous nanoparticles can be seen, 
while residual cells such as erythrocytes (A, black arrow) 
and activated platelets (A, white arrow) were also present in 
the isolate. The nanoparticles had diverse shapes and sizes. 
Tubular structures of different lengths were found (B–F), 
which were more abundant with heparin than with trisodium 
citrate as the anticoagulant. Peculiar structures such as a torus 
(E, white arrows) and starfish (F, black arrow) were found. 
The white arrow in Figure 1F identifies a cell which formed 
protrusions with bulbous ends.
Figure 3 shows some characteristic nanoparticle shapes 
found in an isolate from the blood of a patient with pancreatic 
cancer (female, 60 years). Some rather large fragments with a 
low volume:area ratio (A, B), nanosized discocytes (C), and 
dumb-bell shapes (D) can be seen. Comparison with shapes 
obtained by minimization of the membrane free energy (E, F) 
showed good agreement. This indicates these particles are 
membrane-enclosed entities without an internal structure and 
can therefore be described as vesicles.
To increase the accuracy of the size determinations, samples 
of nanoparticles isolated from the same blood were divided 
into two parts, with one imaged at Åbo Akademi University, 
Figure 1 Scanning electron micrograph of an isolate from peripheral blood of a 
healthy human donor (male, 28 years). A mass of microparticles and numerous 
residual erythrocytes can be seen. The image was taken using a Quanta TM 250 FEG 
(FEI, Hillsboro, OR) scanning electron microscope at FEI Quanta, Eindhoven, The 
Netherlands, by applying 1.5 kV.
Figure  2  Scanning  electron  micrograph  of  chosen  regions  of  an  isolate  from 
peripheral blood of a healthy human donor (male, 28 years). In addition to numerous 
nanoparticles which are present in all the pictures, erythrocytes (A – black arrow, B), 
activated platelets (A – white arrow), tubules (C), tori (E – white arrows), starfish 
(F – black arrow) and a deformed erythrocyte exhibiting protrusion with a bulbous 
end (F – white arrow) were observed. (A – D) images taken using a LEO Gemini 
1530  (LEO,  Oberkochen,  Germany)  scanning  electron  microscope  by  applying 
8 kV (A, C, and D) and 2.7 kV (B), at Åbo Akademi University, Åbo/Turku. Images 
E and F taken by Quanta TM 250 FEG (FEI, Hillsboro, Oregon, OR) scanning electron 
microscope at FEI Quanta, Eindhoven, The Netherlands, by applying 1.5 kV.
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indicate that fragmentation of blood cells occurs during the 
process. Panel A shows the presence of tubular structures 
connected to distal bulbous parts (see also   Figure 3B). Thin 
necks were formed (white arrow), which could have be torn 
by centrifugal shear stress to produce the rather large cell 
fragments found in the isolates. It is evident that the particles 
which we considered to be nanoparticles (Figures 1 and 2) 
attained the sizes and shapes indicated by those of the precur-
sors seen in deformed cells (Figure 4A).
The micrograph shown in Figure 4B was taken close 
to the interface between the isolate and the epruvette wall, 
where the shear force was expected to be greatest. Numerous 
elongated shapes, preferentially oriented in a particular direc-
tion can be seen, indicating that shear stress in the centrifuge 
affects nanoparticle shape.
The process of nanoparticle isolation was studied at 
different temperatures that were kept constant throughout 
Figure 3 Representative characteristic shapes of nanoparticles found in an isolate 
from the blood of a patient with pancreatic cancer (female, 60 years). Shapes include 
shizocytes (A and B), dumbbell (C), submicron discocyte (D), and the corresponding 
shapes calculated by minimization of the membrane free energy (E and F). The shape 
in panel E was obtained for a relative volume v = 36 π V2/3/A3/2 = 0.65, where V is the 
volume of the vesicle, A is the surface area of the vesicle and for the relative average 
mean curvature ,h. = 1/2A ∫(C1 + C2)dA = 1.32, where C1 and C2 are the two 
principal curvatures at a chosen point of the membrane surface and integration is 
performed over the entire surface of the vesicle A. For the shape in panel F, v = 0.55 
and ,h. = 1.055. Intrinsic principal curvatures were equal to 0 for both shapes. 
The images were taken using a LEO Gemini 1530 (LEO, Oberkochen, Germany) 
scanning electron microscope by applying 8 kV at Åbo Akademi University, Åbo/
Turku, Finland.
Table 1 Size (diameter) of nanoparticles isolated from the same 
human  blood  sample  as  observed  by  two  different  scanning 
electron microscopes
Sample NP (n) Diameter ± SD (nm) P
Human blood  
(FEI Quanta)
85 321 ± 130 0.28
Human blood (ÅA) 101 302 ± 131
Notes: Average size of nanoparticles determined by measuring the linear dimensions 
of  nanoparticles  imaged  by  the  scanning  electron  microscopes  at  FEI  Quanta, 
Eindhoven, Netherlands, and at Åbo Akademi University, Abo/Turku, Finland (ÅA). 
The nanoparticles were isolated at room temperature. The P value of the difference 
between the mean sizes obtained by the two microscopes was calculated. 
Abbreviations: NP, nanoparticles; SD, standard deviation.
Åbo/Turku, Finland and the other at FEI Quanta, Eindhoven, 
Netherlands. The isolations were performed at room tempera-
ture (25°C). Drying and gold-sputtering/iridium-coating was 
performed at the two laboratories. The effective diameter of the 
nanoparticles measured in blood isolates by both laboratories 
was about 300 nm (Table 1). The difference between the results 
of the two laboratories was not statistically significant.
Regarding the origin and mechanisms of nanoparticle gen-
eration in the isolates, the structures observed in   Figure 4A 
Figure 4 Deformation of cell-derived material obtained by isolation procedure. 
Deformed cells from the blood of a healthy mare (aged five years) exhibit protrusions 
connected by thin necks, which were torn eventually to yield membrane-enclosed 
cell fragments (A). Close to the tube wall, the shear forces in the centrifuge are 
high and therefore the cell fragments in the isolate from the blood of a healthy 
human donor (male, 28 years) are elongated and exhibit preferential orientation (B). 
The images were taken using a LEO Gemini 1530 (LEO, Oberkochen, Germany) 
scanning electron microscope by applying 8 kV at Åbo Akademi University, Åbo/
Turku, Finland.
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the isolation process using a water-bath and a temperature-
regulated centrifuge. The first population study including 
42 healthy volunteers showed that the concentration of nano-
particles in the isolates determined by flow cytometry was 
lower at higher temperatures (Table 2). Because the accuracy 
of flow cytometry in determining the nanoparticle concentra-
tion is rather poor, a further study was designed to obtain 
a more decisive result. In the second study, all the samples 
were measured using the same setting of the flow cytometer. 
However, this limited the second study to a small number of 
subjects. In the second study, blood was taken from the same 
subjects for all three temperatures investigated. Blood was 
acquired by free flow to minimize activation of platelets in 
the needle that could have been an additional source of dif-
ference between the samples. The results of the second study 
confirmed the results of the first study that the concentration 
of nanoparticles in the isolates was higher at lower isolation 
temperatures (Table 3). However, we observed that the time 
needed to acquire the required volume of blood by free flow 
differed markedly between subjects and also in repetitive 
acquisitions from the same subject, indicating corresponding 
differences in shear stress. Because this could be a source of 
considerable difference in the nanoparticle concentrations in 
isolates, we performed another analysis of the results using 
only data on blood samples from each subject that differed in 
collection time by less than 15 seconds. The data which were 
omitted are marked with asterisks in Table 3. In subject 4, 
all three collection times differed by more than 15 seconds, 
so we retained only one result. The results retained show 
that in all subjects the concentration of nanoparticles in the 
isolates decreased gradually with increasing temperature 
during isolation (Table 3).
We also visualized the platelets in platelet-rich plasma 
at different temperatures in a healthy human (Figure 5A–C) 
and a healthy mare (Figure 5D–F). The respective nanopar-
ticles isolated from these samples are shown in Figure 5G–I. 
At temperatures below room temperature, platelet shapes 
  exhibited filopodia and distortion compared with the rest-
ing discocyte shape in the human and the mare (Figure 5B 
and E). The shapes of the nanoparticles were the same at 
all temperatures (Figure 5G–I). However, their mean size 
measured in human by flow cytometry (Table 4) and in the 
mare by scanning electron microscopy (Table 5) was depen-
dent on the isolation temperature. As shown in Table 4, the 
increase in size with increasing temperature was gradual 
in all subjects (all data included). The differences between 
the size of nanoparticles isolated from mare’s blood at 20°C 
and 37°C and at 30°C and 37°C were considerable (29% 
and 22%, respectively). These differences were statistically 
significant (P , 0.0001) and of sufficient power (P values at 
α = 0.05 were 0.99 and 0.96, respectively) (Table 5). All the 
differences between the mean size of nanoparticles isolated 
from human blood at 4, 20, and 37°C and measured by flow 
cytometry were shown to be statistically significant (Table 4). 
The large size of nanoparticles in the isolates, the shapes 
of the intermediate structures leading to isolated material, 
and the sensitivity of the concentration and mean size of 
nanoparticles to external parameters such as temperature 
indicate that a large pool of nanoparticles were created after 
blood sampling.
Discussion
Our previous experience with microvesiculation was based 
on the process of cell budding observed in vitro.7,8 In experi-
ments with artificially induced vesiculation of erythrocytes, 
the buds observed on the top of the spicules corresponded 
in shape and size to the nanoparticles found in isolates 
 ( Figure 6A and C). Because budding and vesiculation are 
common processes in all cells, we expected that nanoparticles 
created in vivo would also be present in blood and could 
be detected by isolation. However, we experienced poor 
accuracy and repeatability in the isolation procedure (ie, 
nanoparticle concentration) during our attempts to perform 
clinical and population studies (not shown), leading us to 
pose the following questions: Are the nanoparticles found in 
isolates present in blood in vivo? What are the processes lead-
ing to the formation of nanoparticles in isolates? What is the 
content of the isolates? What is the identity of nanoparticles 
in isolates with respect to the mother cell(s)?
To answer these questions we used a combination of meth-
ods to visualize the isolates and cell sediments and performed 
theoretical analyses of shapes, flow cytometry, and population 
studies. Our results indicate that isolates from blood contain a 
mass of submicron-sized particles that have the characteristic 
shapes of membrane-enclosed   fragments with no internal 
Table 2 Concentration of nanoparticles obtained by isolating 
nanoparticles from blood of 42 donors with no record of disease, 
at different temperatures
T (°C) Subjects (n) NP/spheres ± SD P value vs 
37°C (P)
P value vs 
40°C (P)
30 12 2.90 ± 1.85 0.01 (0.64) 0.001 (0.82)
37 17 1.31 ± 1.45 1 0.31 (0.16)
40 13 0.87 ± 0.45 – 1
Notes: Statistical significance of differences (P) and corresponding statistical power 
(P) are shown. NP indicates nanoparticles and T indicates temperature. 
Abbreviations: NP, nanoparticles; SD, standard deviation; vs, versus
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structure. However, these particles are rather large (on 
average .300 nm) compared with the nanovesicles obtained 
from erythrocyte budding in vitro (on average ,180 nm) as 
shown in Figure 6. To provide more independent reliable 
evidence on the size and morphology of nanoparticles, blood 
samples were divided into two parts which were imaged using 
two different scanning electron microscopes. The results 
were in qualitative and quantitative agreement (Table 1). We 
found that isolates may also contain many residual blood 
cells, such as erythrocytes (Figures 1, 2A and B), leukocytes, 
Table 3 Concentration of nanoparticles isolated from human blood at different temperatures and time of blood sampling for seven 
subjects
Subject NP/spheres 
4°C
Time (seconds) 
4°C
NP/spheres  
T = 20°C
Time (seconds) 
20°C
NP/spheres 
T = 37°C
Time (seconds) 
37°C
1 0.54 64 0.58* 110* 0.35 68
2 0.29 55 0.22 57 0.29* 40*
3 1.21 104 0.78* 114* 0.21 90
4 9.34* 72* 0.23* 163* 0.42 55
5 0.58 76 0.32 81 0.17 86
6 0.26* 108* 0.55 82 0.28 84
7 0.90* 64* 0.38 81 0.23 80
Average 1.88 78 0.43 98 0.29 72
Average† 0.65 75 0.38 75 0.28 77
Notes: Data differing in blood sampling time longer than 15 seconds are marked by asterisks. The average marked by a cross was obtained by omitting the data marked by 
asterisks.
Figure 5 Platelets and nanoparticles at different temperatures. Nanoparticles were isolated from platelet-rich plasma of a healthy human donor (female, 28 years) at different 
temperatures (A: 4°C, B: 20°C, C: 37°C), platelets from platelet-rich plasma of a mare (D: 4°C, E: 20°C, F: 37°C), nanoparticles isolated from blood of the mare (G: 4°C, 
H: 20°C, I: 37°C). The images were taken using a LEO Gemini 1530 (LEO, Oberkochen, Germany) scanning electron microscope by applying 8 kV at Åbo Akademi University, 
Åbo/Turku, Finland.
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activated platelets (Figure 2A), and nanotubular structures 
with bulbous ends which appear as hollow tubes attached to 
the fibrin network (Figure 2C). This information is useful for 
gating of the population events detected by flow cytometry.
The concentration of nanoparticles in the isolates was lower 
and their size larger at higher isolation temperatures 
(Tables 2–5). In addition to affecting chemical reactions, 
temperature also affects nonspecific biophysical processes. 
The following equation taking into account centrifugal force, 
buoyancy, and Stokes law governs the sedimentation velocity 
of a spherical particle:
 v  = ∆ρ d2a/18η   (1)
where ∆ρ is the difference in densities of the nanoparticles 
and the medium (plasma), d is the effective diameter of the 
NP, a is the acceleration of the centrifugal force created in the 
centrifuge rotor, and η is the viscosity of the medium.
It follows from equation (1) that both native nanoparticles 
possibly present in blood, and nanoparticles which were 
possibly created after sampling, would sediment more slowly 
at lower temperatures due to the higher viscosity of plasma 
at these temperatures. Therefore, clearance of cells from the 
upper part of the tube used to isolate nanoparticles during 
the first centrifugation is less effective. Cells remaining in 
this compartment may shed nanoparticles into the sample 
during centrifugation. We also observed that platelets become 
activated below room temperature and increasingly deform 
with decreasing temperature (Figure 5). Activation of plate-
lets causes changes in the integrity of their cytoskeleton and 
renders the cells prone to fragmentation, thereby contributing 
to an increased number of nanoparticles in the isolates at 
lower temperatures. All the above facts explain the lower con-
centration of nanoparticles we observed in isolates prepared 
at higher temperature (Tables 2 and 3). Because the effects 
on nanoparticle concentration of factors that determine the 
sedimentation speed of existing nanoparticles and the cre-
ation of new nanoparticles during the first step of isolation are 
synergistic, we could not distinguish between their respective 
contributions to the overall effect. However, the mean size 
of the nanoparticles was also different at different isolation 
temperatures. If isolation primarily yields the nanoparticles 
that were present in blood in vivo, the average size of nano-
particles present in the upper compartment of plasma after 
the first centrifugation should be smaller at higher tempera-
tures according to equation (1), and the clearance of larger 
nanoparticles would be more effective. Assuming that the 
second and the third centrifugation collects nanoparticles in 
the pellet, the average size of nanoparticles in isolates would 
be expected to be smaller at higher temperatures. In contrast, 
Figure 6 Budding of membranes. (A) Budding of erythrocytes induced by adding 
detergent to the suspension of erythrocytes (scanning electron microscopy performed 
at Åbo Akademi University, Åbo/Turku, Finland). (B) A budding erythrocyte found 
in an isolate from human blood with numerous nanoparticles (scanning electron 
microscopy performed at FEI Quanta, Eindhoven, The Netherlands). (C) Nanoparticles 
isolated from suspension of erythrocytes with added detergent. (D) Precursors of 
nanoparticles appearing at the top of the echinocyte spicules. (A, C, and D images 
taken using a LEO Gemini 1530 (LEO, Oberkochen, Germany) scanning electron 
microscope by applying 8 kV, at Åbo Akademi University, Åbo/Turku, Finland. Image 
(C) taken by Quanta TM 250 FEG (FEI, Hillsboro, OR) scanning electron microscope 
at FEI Quanta, Eindhoven, The Netherlands, by applying 1.5 kV). Image in Panel B was 
taken from Šuštar et al.46
Table 4 Mean of the parameter representing flow cytometric 
measurement of light scattering in the forward direction (relative 
units) at different temperatures
Subject Mean FS 
T = 4°C
Mean FS 
T = 20°C
Mean FS 
T = 37°C
1 1.2 2.1 2.1
2 1.4 1.7 2.7
3 0.9 1.3 2.3
4 0.9 1.8 2.0
5 1.5 2.1 2.4
6 1.7 1.9 2.4
7 1.3 1.8 1.9
Average 1.3 1.8 2.3
Note: This parameter represents the mean size of nanoparticles. 
Abbreviation: FS, forward scatter.
Table 5   Size  of  nanoparticles  isolated  from  mare’s  blood  at 
different  temperatures  (diameter  measured  from  scanning 
electron microscope images taken at Åbo Akademi University, 
Åbo/Turku, Finland)
T (°C) NP  
measured (n)
Diameter ±  
SD (nm)
P value vs  
30°C (P)
P value vs 
37°C (P)
20 44 273 (82) 0.331 (0.166) ,0.0001 
(0.99)
30 51 291 (101) 1 ,0.0001 
(0.95)
37 67 362 (100) 1
Abbreviations: NP, nanoparticles; SD, standard deviation.
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we observed that nanoparticles are larger when isolated at 
higher temperatures (Tables 4 and 5).
Staining with antibodies for platelet origin (anti-CD42bPE 
and anti-CD31FITC positive events) showed that the major-
ity (70%) of nanoparticles contain receptors derived from 
  platelets.46 This finding agrees with previous reports.40 However, 
it was unclear how particles sized 300 nm or greater that were 
mainly quasiglobular-shaped could be obtained by budding 
of activated platelets. For example, the filopodia of activated 
platelets are thinner (Figure 5A–F), so if these were pinched 
off from the mother cell, the nanoparticles produced would be 
evidently smaller and/or tubular. Despite the considerable evi-
dence that platelets are the main origin of nanoparticles in blood 
isolates,40 by using the described protocol for isolation we found 
no correlation between the number of platelets in blood and the 
number of nanoparticles found in blood isolates (Table 6). This 
relationship should be expected if the nanoparticles found in 
isolates were predominantly present in blood in vivo.
Platelets are affected by shear stress in the needle dur-
ing blood sampling. Assuming laminar stationary flow of a 
Newtonian viscous fluid and the validity of the Poiseuille-
Hagen law, the velocity in the direction of flow is subject to 
a parabolic profile that is dependent on the distance from the 
center of the needle. During free flow, the flow rate is deter-
mined by the difference between the pressure in the vein and 
atmospheric pressure which results in the rather slow dripping 
of blood. The gradient of velocity determines the shear force 
that is greatest near the inner wall of the needle:
  F = 8ηVl/tR2  (2)
where V is the volume of blood, l is the length of the needle, 
t is the time required to acquire the blood, and R is the inner 
radius of the needle.
The variation in time that reflects the speed of blood 
in the needle may be the cause of the poor accuracy when 
determining the concentration of nanoparticles. In the second 
experiment that assessed the temperature dependence of the 
nanoparticle concentration, we measured the time required 
to acquire 2.9 mL of blood. Because it is still unclear how 
shear stress affects the concentration of nanoparticles in iso-
lates, we omitted those measurements from the final analysis 
that differed in collection time by more than 15 seconds. 
The remaining data showed monotonous behavior in the 
relationship of nanoparticle concentration on temperature 
in all seven subjects. The lower pressure in evacuated tubes 
used for blood sampling results in greater flow and therefore 
shorter times to acquire the same volume of blood, with a 
correspondingly larger velocity of blood and shear stresses 
in the needle. A thorough theoretical and experimental 
analysis of blood flow in the needle is required to optimize 
blood sampling.
The isolation procedure depends on external parameters 
that cannot be kept constant with the existing equipment and 
protocol. This explains the poor repeatability and accuracy of 
nanoparticle isolation in different experiments and certainly 
adds to the lack of correlation we observed between the 
concentration of nanoparticles in isolates and the concen-
tration of platelets in blood. However, another explanation 
consistent with the above findings is that the majority of 
nanoparticles are created after blood sampling, and accord-
ingly the results reflect the properties and composition of 
blood cells and plasma. For example, membrane and plasma 
constituents may affect membrane curvature,47–49 which is the 
basic mechanism underlying the budding and vesiculation of 
membranes. Controlled manipulation of the size of the cell 
fragments (nanoparticles) could be advantageous, as avoiding 
production of fragments of the size of immune complexes 
(mean diameter approximately 150 nm) may avoid problems 
with artefacts when measuring the nanoparticle concentration 
by flow cytometry.50
The properties of blood cells and plasma may have 
an important influence on the state of the isolate. One can 
interpret the alteration of blood cells in cancer patients by 
Table 6 Correlation between nanoparticle concentration in isolate and platelet concentration in blood in six experiments involving 
healthy human donors
Experiment Subjects (n) Platelets ± SD [109/L] NP/spheres ± SD Pearson coefficient Statistical significance (P)
1 64 250 ± 46 0.67 ± 0.33 0.15 0.38
2 25 250 ± 45 0.66 ± 0.33 0.11 0.63
3 24 244 ± 51 2.52 ± 1.86 0.23 0.35
4 27 234 ± 57 1.82 ± 1.03 -0.03 0.88
5 25 235 ± 69 1.03 ± 0.55 -0.06 0.78
6 28 238 ± 53 1.11 ± 0.72 0.02 0.90
Abbreviations: NP, nanoparticles; SD, standard deviation.
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the presumable integration of native tumor cell-derived 
nanoparticles into their membranes. Therefore, blood cells, 
especially platelets, may convey tumor cell material to distal 
cells and render it functional by inducing processes in these 
cells.51–53 It has been suggested that metastases are seeded by 
tumor cells and that the probability of this happening is greater 
when microemboli composed of tumor cells and platelets 
travel slowly in capillaries, thereby enhancing the probability 
of tumor cells entering the tissues through the endothelium.54 
Platelets are known to adhere to tumor cells and shield them 
from attack by leukocytes.54 Indeed, there is evidence that 
platelets support tumor metastasis54 and platelet counts are 
related to prognosis in cancer patients.55,56 Because tumor 
cells are unlikely to be found in vivo in patients, the above 
hypothesis is based on cancer induction by injection of tumor 
cells directly into the blood of animals. On the other hand, it 
appears likely that native nanoparticles shed by cancer cells 
are the origin of metastases, either as vehicles or as media-
tors of transport by mobile cells, most probably platelets. It 
has been reported that nanoparticles shed from cells interact 
with other cells,57–60 so it is possible that material shed from 
blood cells is exchanged constantly between cells via native 
nanoparticles. Because platelets are prone to vesiculate, the 
material shed during this process is likely to be found in other 
cells, such as erythrocytes, leukocytes, and endothelial cells. 
The nanoparticle-mediated exchange of material between 
cells may explain the intriguing data of Boilard et al, who 
found platelet-derived material, but no platelets, in the syn-
ovial fluid of patients with rheumatoid arthritis.58
Figure 6 shows budding of erythrocytes and the respec-
tive isolated microvesicles. In the sample shown in Panel A, 
budding was induced by adding echinocytogenic molecules 
to the suspension, while in the sample shown in Panel B, 
echinocytosis took place during isolation due to mechanical 
and thermal stress. Regardless of the mechanism, the shapes 
of the echinocytes and the buds are similar. It would therefore 
be expected that erythrocyte-derived microvesicles (Panel C) 
are considerably smaller than the nanoparticles observed 
in Figures 1–5 and would not have been detected by flow 
cytometry.
The shapes shown in Figure 3E and F were calculated 
theoretically by minimization of the membrane free energy 
as described elsewhere.45 It was assumed that the vesicle has 
no internal structure and that its shape was determined by the 
properties of the membrane. The membrane free energy was 
derived using the energies of individual membrane constitu-
ents and for simplicity, it was assumed that all constituents 
were equal. Entropic effects were also taken into account. The 
free energy obtained was determined by a thermodynamic 
expression for the elastic energy using statistical physics 
methods.44,45 The calculated shapes of minimal elastic energy 
were characterized by a high degree of symmetry and smooth 
contours that avoided strong bending, which is energetically 
unfavorable. Vesicles undergo fluctuations in shape due 
to thermal effects, so their instantaneous shapes deviate 
somewhat from the ideal morphology predicted by theory 
and calculations. Nevertheless, matching of the appearance 
of the observed and the calculated shapes of blood-derived 
nanoparticles was excellent in our study (Figure 3C–F). It 
can also be seen in Figures 1 and 2 that the contours of the 
nanoparticles are highly symmetrical and smooth, indicating 
that these shapes correspond to microvesicles with no internal 
structure. Calculation of shape changes in the sedimentation 
field may be of considerable help in revealing the mecha-
nisms of cell budding and vesiculation during centrifugation 
and remains a task for future research.
Conclusion
By visualizing isolates and comparing theoretically obtained 
shapes with observed shapes, we showed that submicron-sized 
particles were present in the material obtained from blood by 
centrifugation and washing. However, analysis of the nano-
particle shapes and sizes obtained indicates that a large pool 
of these nanoparticles is composed of cell fragments, which 
were most likely formed as a result of mechanical stress dur-
ing centrifugation and also thermal stress during isolation. 
The concentration, size, and identity of nanoparticles in the 
isolates appear to depend on the properties of blood cells and 
the surrounding medium, which may be altered by disease. 
The isolated nanoparticles, therefore, represent a clinically 
relevant parameter, even though they may have been created 
after blood sampling.
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